Fig. 2.11 Recent acyclic tripeptide inhibitors.

shows moderate replicon potency (EC50 = 400 nM), good oral bioavaila-bility and excellent liver exposure [145]. The replicon system was also used to obtain resistance mutations for this compound. The amino acid substitutions A156S [91] or A156T [146] significantly weaken binding. Interestingly, A156S does not significantly affect the binding of the tripeptide BILN

Was this article helpful?

0 0

Post a comment